PDAC

Oncology·MeSH: Carcinoma, Pancreatic Ductal

19 drugs in development·12 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
[18F]FAPI-74 PET/CT	ENANTA PHARMACEUTICALS INC (ENTA)
batiraxcept	Aravive, Inc. (ARAV)
CAN-2409	Candel Therapeutics, Inc. (CADL)
daraxonrasib	REVOLUTION MEDICINES, INC. (RVMD)
mFOLFIRINOX	Tango Therapeutics, Inc. (TNGX)

Phase 2(3)

Drug	Company
cetuximab	Verastem, Inc. (VSTM)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)
vs-7375	Verastem, Inc. (VSTM)

Phase 1(5)

Drug	Company
68ga-dfc413	Novartis AG (NVS)
68ga-nns309	Novartis AG (NVS)
mFOLFIRINOX	BioNTech SE (BNTX)
mvt-1075	MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)
mvt-2163	MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX)

Preclinical(2)

Drug	Company
neo-stc-01	Neon Therapeutics, Inc. (NTGN)
VPS4A inhibitors (novel series)	Calithera Biosciences, Inc. (CALA)

Phase 1/Phase 2(4)

BioSniper tracks 19 drugs in development for PDAC across 12 companies.

There are 11 clinical trials targeting PDAC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.